Literature DB >> 12589864

Gastric cancer epidemiology and risk factors.

Jon R Kelley1, John M Duggan.   

Abstract

We performed a detailed analysis of the epidemiology of gastric carcinoma, based upon a review of the literature in English. The analysis reveals many puzzling features. There has been a steady fall in the incidence of gastric carcinoma in most societies studied, but a more recent steady rise in the incidence of adenocarcinoma of the cardia and lower esophagus, largely confined to White males. Although the evidence for a major role for Helicobacter pylori (H. pylori) in the etiology of gastric corpus cancer is compelling; in Western society, it probably accounts for fewer than half the cases. The relative roles of dietary constituents such as salt and nitrites and the phenotyping of H. pylori in causation and the beneficial effects of a high fruit and vegetable diet and an affluent lifestyle, for all of which there is some evidence, are yet to be quantified.

Entities:  

Mesh:

Year:  2003        PMID: 12589864     DOI: 10.1016/s0895-4356(02)00534-6

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  219 in total

1.  Selection criteria for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Ingmar Königsrainer
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

2.  The prognostic significance of p53 expression in gastric cancer: a meta-analysis.

Authors:  Kongkong Wei; Lei Jiang; Yaoyao Wei; Yufeng Wang; Xuankun Qian; Qiang Dai; Quanlin Guan
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-15       Impact factor: 4.553

3.  Gastric cancer-a clinicopathological study in a tertiary care centre of North-eastern India.

Authors:  Arun Kumar Barad; Sanjeet Kumar Mandal; Hiriyur S Harsha; Birkumar M Sharma; Th Sudhirchandra Singh
Journal:  J Gastrointest Oncol       Date:  2014-04

4.  Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer.

Authors:  Carlo Barone; Michele Basso; Giovanni Schinzari; Carmelo Pozzo; Nunziatina Trigila; Ettore D'Argento; Michela Quirino; Antonio Astone; Alessandra Cassano
Journal:  Gastric Cancer       Date:  2007-06-25       Impact factor: 7.370

5.  Epidemiology of upper gastrointestinal cancers in Iran: a sub site analysis of 761 cases.

Authors:  Noushin Taghavi; Dariush Nasrollahzadeh; Shahin Merat; Abbas Yazdanbod; Mahshid Hormazdi; Masoud Sotoudeh; Shahriar Semnani; Farhad Eslami; Haji-Amin Marjani; Saman Fahimi; Hooman Khademi; Reza Malekzadeh
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

6.  Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study.

Authors:  Thomas Makatsoris; Pavlos Papakostas; Haralabos P Kalofonos; Ioannis Xanthakis; Dimitrios Tsavdaridis; Gerasimos Aravantinos; Helen Gogas; George Klouvas; Paris Kosmidis; Dimitrios Pectasides; George Fountzilas
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

7.  Expression of SIP1 is strongly correlated with LDHA and shows a significantly poor outcome in gastric cancer.

Authors:  Xuren Sun; Zhe Sun; Zhi Zhu; Chenyan Li; Junyan Zhang; Huimian Xu; Mingjun Sun
Journal:  Tumour Biol       Date:  2015-04-26

8.  Low expression of ERK signaling pathway affecting proliferation, cell cycle arrest and apoptosis of human gastric HGC-27 cells line.

Authors:  BeiLi Zhang; Yan Gu
Journal:  Mol Biol Rep       Date:  2014-02-20       Impact factor: 2.316

Review 9.  Gastrin May Mediate the Carcinogenic Effect of Helicobacter pylori Infection of the Stomach.

Authors:  Helge L Waldum; Øyvind Hauso; Øystein F Sørdal; Reidar Fossmark
Journal:  Dig Dis Sci       Date:  2014-12-06       Impact factor: 3.199

Review 10.  [Medicinal prevention of gastrointestinal tumors: aspirin, Helicobacter and more?].

Authors:  J C Becker; W Domschke; T Pohle
Journal:  Internist (Berl)       Date:  2006-12       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.